Singapore markets open in 7 hours 42 minutes

Ensysce Biosciences, Inc. (ENSC)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
0.3900-0.0450 (-10.34%)
As of 12:54PM EDT. Market open.

Ensysce Biosciences, Inc.

7946 Ivanhoe Avenue
Suite 201
La Jolla, CA 92037
United States
858 263 4196
https://www.ensysce.com

Sector(s)Healthcare
IndustryBiotechnology
Full-time employees7

Key executives

NameTitlePayExercisedYear born
Dr. D. Lynn Kirkpatrick Ph.D.President, CEO & Director414.77kN/A1957
Mr. David C. Humphrey CPACFO, Secretary & Treasurer348.15kN/A1969
Mr. Geoffrey BirkettChief Commercial Officer322kN/A1963
Dr. Jeffrey Millard Ph.d.Chief Operating OfficerN/AN/A1976
Dr. William K. Schmidt Ph.D.Chairman of Clinical Advisory Board & Chief Medical OfficerN/AN/A1951
Dr. Linda Pestano Ph.D.Chief Development OfficerN/AN/A1970
Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection (TAAP) platform, an abuse-resistant opioid prodrug technology; and Multi-Pill Abuse Resistance (MPAR) platform, an over-dose protection opioid prodrug technology. The company is developing PF614, a TAAP oxycodone prodrug candidate for the treatment of acute or chronic pain; and PF614-MPAR, a combination product of PF614 and nafamostat for overdose protection against excessive oral ingestion, as well as an oral and inhalation drug product of nafamostat for use against coronaviral infections and other pulmonary diseases, such as cystic fibrosis. It is also developing PF614, an extended-release oxycodone-derivative that releases clinically effective oxycodone; PF329 for pain with abuse protection; PF8001 and PF8026 are extended and immediate-release prodrugs of amphetamine for ADHD; and PF9001 to treat Opioid use disorder. The company was founded in 2003 and is based in La Jolla, California.

Corporate governance

Ensysce Biosciences, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.